Stock market analyst Hitesh Chotalia has maintained 'buy' rating on Glenmark Pharmaceutical Ltd stock to achieve short term target of Rs 315.

According to analyst, the interested investors can buy the stock with strict stop loss of Rs 280.

The stock of the company, on Sep 01, closed at Rs 288.65 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 303.80 and a low of Rs 214.60 on BSE.

Current EPS & P/E ratio stood at 16.05 and 18.09 respectively.

Glenmark Pharmaceuticals Ltd has made announcement about the discovery of a new chemical unit called `GRC 17536`.

The novel NCE program is eyeing TRPAI receptor adversary for ache and respiratory troubles.

Drug maker Glenmark Pharmaceuticals has announced that it has bagged US health regulator's sanction to market generic trospium tabs in the US market.

Glenmark Pharma's US-based arm, Glenmark Generics Inc, has received green signal from USFDA for marketing as well as distribution of trospium tabs in the potency of 20 mg.

Generic trospium tablets are used for the treatment of urinary troubles.